KAEL-Gemvax Of S. Korea Says Multi-cancer Vaccine May Launch Early
This article was originally published in PharmAsia News
Executive Summary
South Korea's KAEL-Gemvax says a cancer vaccine it is developing to be less invasive than conventional treatments is showing promise as it moves through Phase III trials